Showing 1611-1620 of 4118 results for "".
DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PDermWireTV: Derm Salaries Down, Allergan Eyes Soliton, Emsculpt Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-derm-salaries-down-allergan-eyes-soliton-emsculpt-week/19941/Just under half of all physicians in the US are employed in physician-owned medical practices, new data from the American Medical Association show. Medscape’s annual Physician Compensation Report reveals that physicians overall saw a reduction in income due to the COVID-19 pandemic; income for dermOpportunities and Barriers in Teledermatology
https://practicaldermatology.com/conferences/aad-2021/opportunities-and-barriers-in-teledermatology/19923/Dermatologists' participation in telemedicine has increased exponentially over the past year. But what does the future hold? What opportunities exist and what challenges remain? Jules Lipoff, MD weighs in.Anatomy Lesson: Targeting the Underlying Cause of Wrinkles with Injections
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/anatomy-lesson-targeting-the-underlying-cause-of-wrinkles-with-injections/19778/Patients need to understand that addressing the underlying causes of wrinkles and folds such as changes in bony structures with injectables will provide a more natural result than simply chasing wrinkles and folds, says Jeanette M. Black, MD.IL-23 Inhibitors: Update on Safety and Dosing
https://practicaldermatology.com/topics/psoriasis/il-23-inhibitors-update-on-safety-and-dosing/19773/With more experience using IL-23 inhibitors to treat psoriasis, dermatologists are seeing high levels of patient satisfaction and no new safety signals. Jennifer Cather, MD assesses the clinical experience.Where There's a WLL
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/where-theres-a-wll/19711/The Woodward Laser Eyelash Lift (WLL) uses an excision laser to provide a long-term lifting of the eyelashes. Creator Julie Woodward, MD describes the technique.Inclusion is In
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/inclusion-is-in/19704/Until you know your biases, you can't address them, says Jeanine Downie, MD. Inspired by the Obagi Skinclusion inititiative, she addresses the problem of bias in aesthetic medicine.PD Asks: What would your staff say is the one thing you do that most aggravates them?
https://practicaldermatology.com/topics/practice-management/pd-asks-what-would-your-staff-say-is-the-one-thing-you-do-that-most-aggravates-them/19695/John E. Harris, MD, PhD explains why his frequent travel might leave his staff feeling a bit annoyed at times!Approval for Evolus; Remembering Vic Narurkar, MD
https://practicaldermatology.com/topics/practice-management/dermwiretv-approval-for-evolus-remembering-vic-narurkar-md/19553/The FDA has approved Jeuveau, the lead product from Evolus, Inc. David Moatazedi, President and CEO of Evolus, and Michael Jafar, Chief Marketing Officer at Evolus, comment on market potential for the new product.Twenty-eight percent of physicians say the prior authorization process required by heal